Reham Abdelkader | Pharmacology | Best Researcher Award

Published on by Health Scientists

Prof. Reham Abdelkader | Pharmacology | Best Researcher Award 

Head of department | German university in Cairo | Egypt

Dr. Reham Mahmoud Abdel-Kader, Professor of Pharmacology and Toxicology and Chair of the Department at the German University in Cairo, is a distinguished biomedical scientist whose research bridges molecular pharmacology, neurodegenerative diseases, and cancer biology with translational therapeutic innovation. Her scientific contributions focus on elucidating mitochondrial dysfunction, neuroinflammation, and cellular bioenergetics as critical mechanisms in Alzheimer’s disease and oncological disorders, advancing targeted treatment approaches through nanotechnology and pharmacogenomic insights. Dr. Abdel-Kader has established two active research groups investigating Alzheimer’s pathology and mitochondrial roles in breast cancer progression, fostering a strong translational link between bench discovery and therapeutic development. She has published widely in internationally recognized journals in pharmacology, neurobiology, and molecular medicine, and her work has received global recognition through prestigious conference presentations and features in leading scientific outlets. Her research has attracted significant international funding from agencies such as the Swiss National Science Foundation, DAAD-BMBF, and the Science and Technology Development Fund, reflecting the impact and sustainability of her scientific endeavors. A committed academic leader, she has played a vital role in curriculum development, accreditation processes, and capacity-building initiatives that enhance educational quality and research excellence within her institution. Dr. Abdel-Kader actively collaborates with leading scientists and institutions across Europe, including partnerships in Germany and Switzerland, fostering international scientific exchange and innovation. Her patent in nanocomposite synthesis further underscores her commitment to bridging pharmaceutical research and technology-based solutions. Through her scholarly rigor, mentorship, and collaborative leadership, Dr. Abdel-Kader continues to contribute significantly to global pharmacological sciences and to shaping the next generation of health researchers dedicated to advancing human health and societal well-being.

Profiles: Google Scholar | ORCID

Featured Publications

1. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., & others. (2007). Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease? Antioxidants & Redox Signaling,

2. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., & others. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research,

3. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., & others. (2012). Mitochondrial dysfunction—A pharmacological target in Alzheimer’s disease. Molecular Neurobiology,

4. Franke, C., Nöldner, M., Abdel-Kader, R., Johnson-Anuna, L. N., Wood, W. G., & others. (2007). Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiology of Disease

5. Eckert, G. P., Schiborr, C., Hagl, S., Abdel-Kader, R., Müller, W. E., & Rimbach, G. (2013). Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochemistry International.

Sina Andalib | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Sina Andalib | Pharmacology | Best Researcher Award

correspond author | Zanjan university of medical sciences | Iran

Dr. Sina Andalib is an Associate Professor at the Department of Pharmacology, Pharmacy Faculty, Zanjan University of Medical Sciences, Iran. He earned his Doctor of Veterinary Medicine (DVM) from Tabriz Azad University in 2005, focusing on anti-inflammatory effects of statins, and completed his PhD at Tabriz University of Medical Sciences in 2013, investigating the cardioprotective effects of Atorvastatin in isoproterenol-induced heart failure in rats. Dr. Andalib’s research spans pharmacology, neurodegenerative diseases, drug delivery systems, and natural product therapeutics, with a particular focus on Alzheimer’s disease, Parkinson’s disease, diabetes, and cancer. He has supervised numerous PhD and PharmD theses exploring innovative nanoparticle-based drug delivery, herbal and synthetic compound interventions, and molecular mechanisms underlying neuroprotection and cardioprotection. His work has been published extensively in high-impact international journals including ACS Chemical Neuroscience, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and European Journal of Pharmacology, covering topics such as nanocomposite hydrogels for wound healing, fullerene-based interventions in Alzheimer’s models, and polypharmacological effects of anticancer compounds. Dr. Andalib has contributed to several internationally collaborative projects, including the development of nanocomposites for neuroprotection and polypharmacological studies of anticancer compounds in organoid models. He has received recognition for his scientific contributions in pharmacology and neurotherapeutics and serves on editorial boards of peer-reviewed journals in pharmacology and drug delivery research. In addition to his research, he holds leadership roles at Zanjan University, including Head of the Department of Pharmacology and Toxicology and Head of the Education Development Office, fostering academic development and innovative research in pharmaceutical sciences. He has 751 citations from 39 documents with an h-index of 15.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Danafar, H., Sharafi, A., Kheiri Manjili, H., & Andalib, S. (2017). Sulforaphane delivery using mPEG–PCL co-polymer nanoparticles to breast cancer cells.

2. Garjani, A., Fathiazad, F., Zakheri, A., Akbari, N. A., Azarmie, Y., Fakhrjoo, A., et al. (2009). The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats.

3. Barzegar-Jalali, M., Alaei-Beirami, M., Javadzadeh, Y., Mohammadi, G., et al. (2012). Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions.

4. Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., & Garjani, A., et al. (2011). Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.

5. Abedimanesh, N., Asghari, S., Mohammadnejad, K., Daneshvar, Z., et al. (2021). The anti-diabetic effects of betanin in streptozotocin-induced diabetic rats through modulating AMPK/SIRT1/NF-κB signaling pathway.